Receptor mechanisms of prenodal lymphatic constriction by dopamine.
It has been proposed that alterations in lymphatic smooth muscle activity significantly impact lymphatic function. Numerous endogenous vasoactive agents are known to constrict prenodal lymph vessels. In this study, we assessed the ability of dopamine to alter lymphatic smooth muscle tone in perfused prenodal lymph vessels. Additionally, the receptor mechanisms of dopamine's actions were elucidated. Both intralymphatic (i.l.) and intra-arterial (i.a.) dopamine significantly increased lymphatic perfusion pressure. The increase in lymphatic pressure was completely blocked by i.a. phentolamine, suggesting involvement of alpha(1)- and/or alpha(2)-adrenoreceptors. Intra-arterial infusion of the specific alpha(1)-receptor antagonist prazosin completely abolished the constriction seen during i.l. phenylephrine but only attenuated that produced by dopamine. Intralymphatic infusion of the DA(1)-receptor agonist SKF 82526-J and the DA(2)-receptor agonist LY 171555 caused significant relaxation of lymph vessels that had been previously constricted by i.a. norepinephrine infusion. These data indicate that the constriction produced by dopamine, in the concentrations employed in this study, is mediated by both alpha(1)- and alpha(2)-adrenoreceptors. These lymph vessels do contain both DA(1)- and DA(2)-receptors but stimulation of these receptors results in lymphatic smooth muscle relaxation.
Dobbins
David E
DE
Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814-4799, USA. ddobbins@usuhs.mil
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D004298:Dopamine / Q000494:pharmacology*; D005260:Female; D018818:Fenoldopam / Q000494:pharmacology; D005552:Forelimb; D007261:Infusions, Intra-Arterial; D007272:Injections, Intralymphatic; D042601:Lymphatic Vessels / Q000187:drug effects / Q000502:physiology* / Q000601:surgery; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology*; D009638:Norepinephrine / Q000494:pharmacology; D010477:Perfusion; D010646:Phentolamine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism
C416545:4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrzolo(3,4-g)quinoline; D011804:Quinolines; D011942:Receptors, Adrenergic, alpha; D011954:Receptors, Dopamine; D010656:Phenylephrine; D018818:Fenoldopam; D004298:Dopamine; D009638:Norepinephrine; D011224:Prazosin; D010646:Phentolamine